In Vivo Liquid Biopsy of Melanoma (Cytophone)

Launched by CYTOASTRA · Jun 28, 2024

Keywords

ClinConnect Summary

This clinical trial, called the Cytophone study, is looking at a new, non-invasive method for detecting melanoma, a serious type of skin cancer. The Cytophone system can find and count tiny melanoma cells in the blood, which is important because these cells can indicate whether the cancer has spread, or metastasized, to other parts of the body. One of the key advantages of this test is that it doesn't require any needles or skin cuts, making it easier and more comfortable for patients. The goal of the trial is to see if this new test can help identify risks of cancer recurrence or progression earlier than current methods.

To participate in this trial, individuals must have a confirmed diagnosis of melanoma and be willing to give their consent to join the study. Participants will need to be able to sit still for up to 60 minutes during the testing process. However, some people are not eligible, including those with certain health conditions, pregnant or breastfeeding women, and those who cannot provide informed consent due to mental or other serious health issues. By taking part in this study, participants may help researchers learn more about how to detect melanoma more effectively, potentially benefiting future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological documented diagnosis of melanoma;
• • Participants having provided informed consent with signature on informed consent form: the informed consent process should be complete with full discussion of all requirements and possible risks;
• • Must be able to sit for up to 60 minutes.
• Exclusion Criteria:
• • Unable to provide informed consent to participate in the study, such as a mental condition rendering the participant unable to understand the nature, scope, and possible consequences of the study;
• • Clinically relevant cardiovascular, hepatic, neurological (e.g., evidence of organic brain syndrome), endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the participant at risk by participating in the study;
• • Persistent significant or severe infection, either acute or chronic;
• • Pregnant or breast-feeding women or those who plan to become pregnant during the study;
• • Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy;
• • Any known history of severe preexisting constipation.